Jadwal Sholat

Memuat jadwal sholat…

Kedokteran & Kesehatan editorial

Open AccessOA2024

Natural Products Have Increased Rates of Clinical Trial Success throughout the Drug Development Process

Natural products and their derivatives show higher success rates in clinical trials and lower toxicity compared to synthetic compounds, according to an analysis of patent and clinical trial data.
D. Domingo-Fernándéz; Yojana Gadiya; A. Preto; Christoph A. Krettler; S. Mubeen; August Allen; David Healey; Viswa Colluru· Journal of Natural Products· 2024· DOI 10.1021/acs.jnatprod.4c00581

The core problem

Natural products (NPs) and their derivatives have long been recognized as a rich source of therapeutic agents. A significant proportion of approved drugs are either natural products or inspired by them. However, the pharmaceutical industry has increasingly favored synthetic compound libraries in drug discovery, partly due to challenges in isolating and synthesizing NPs. This study aims to quantify the success rates of NPs in drug development by examining patent applications as a proxy for early-stage discovery and clinical trial data for later stages. The authors also investigate toxicity profiles to understand the factors contributing to the observed success rates. The central hypothesis is that NPs and their derivatives exhibit higher success rates in clinical trials and lower toxicity, making them valuable starting points for drug development.

Innovation

The study employed a multi-pronged approach:

1. **Patent Analysis**: Patent applications spanning several decades were analyzed to estimate the proportion of NP, NP-derived, and synthetic-compound-based patents. This served as a proxy for early drug development stages.
2. **Clinical Trial Data**: Data from clinical trials phases I to III were assessed to track the progression of NP, NP-derived, and synthetic compounds. The proportions of each category at each phase were compared.
3. **Toxicity Studies**: In vitro and in silico toxicity studies were reviewed to compare the toxicity profiles of NPs and their derivatives with synthetic counterparts.

The analysis focused on calculating the percentages of each compound class at different stages and evaluating trends across phases. The authors did not specify the exact number of patents or trials analyzed, but the findings are based on aggregated data from public databases.

Introduction
Natural products (NPs) and their derivatives have long been recognized as a rich source of therapeutic agents. A significant proportion of approved drugs are either natural products or inspired by them. However, the pharmaceutical industry has increasingly favored synthetic compound libraries in drug discovery, partly due to challenges in isolating and synthesizing NPs. This study aims to quantify the success rates of NPs in drug development by examining patent applications as a proxy for early-stage discovery and clinical trial data for later stages. The authors also investigate toxicity profiles to understand the factors contributing to the observed success rates. The central hypothesis is that NPs and their derivatives exhibit higher success rates in clinical trials and lower toxicity, making them valuable starting points for drug development.

Why it matters

The findings suggest that while NPs are underrepresented in early-stage patent filings (23% vs 77% for synthetics), they exhibit higher success rates as they progress through clinical trials. The increasing proportion of NPs from phase I to phase III implies that NPs are more likely to advance to later stages, possibly due to better efficacy or safety profiles. The toxicity data support this, showing that NPs are less toxic alternatives.

The inverse trend for synthetic compounds—decreasing from phase I to phase III—indicates higher attrition rates, which could be attributed to toxicity or lack of efficacy. These results highlight the potential benefits of prioritizing NPs and their derivatives in drug discovery. The authors suggest that NPs offer valuable scaffolds for developing new therapeutics with improved success probabilities.

However, the study has limitations. The use of patents as a proxy for early discovery may not capture all NP research, and the clinical trial data might be influenced by reporting biases. Future research could explore specific therapeutic areas where NPs excel and investigate the mechanisms behind their lower toxicity.

In conclusion, this study provides quantitative evidence that NPs and their derivatives have higher clinical trial success rates and lower toxicity, supporting their continued exploration in drug development.

Who should read this

Pembaca Research Digest dan praktisi rumpun ini.

Opening member content…